Phase II study of amrubicin (AMR) combined with carboplatin (CBDCA) for refractory relapsed small cell lung cancer (SCLC): North Japan Lung Cancer Group 0802.
Ryota Saito
No relevant relationships to disclose
Akira Inoue
No relevant relationships to disclose
Shunichi Sugawara
No relevant relationships to disclose
Satoshi Oizumi
No relevant relationships to disclose
Makoto Maemondo
No relevant relationships to disclose
Koichi Okudera
No relevant relationships to disclose
Toshiro Suzuki
No relevant relationships to disclose
Kazuhiro Usui
No relevant relationships to disclose
Masao Harada
No relevant relationships to disclose
Naoto Morikawa
No relevant relationships to disclose
YUkihiro Hasegawa
No relevant relationships to disclose
Osamu Ishimoto
No relevant relationships to disclose
Tomohiro Sakakibara
No relevant relationships to disclose
Hajime Asahina
No relevant relationships to disclose
Toshihiro Nukiwa
No relevant relationships to disclose